OR WAIT null SECS
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
There are several potential treatments on the horizon for C difficile infections.
The state of care for C difficile infections is improving rapidly by the day.
Fecal microbiota transplantation (FMT), live microbiome therapeutics (LMT), and new antibiotics have drastically led to improving care.
And a lot of the measures put in place during the COVID-19 pandemic has led to a drop in hospital-acquired infections.
With the state of care improving, new research suggests C difficile cases are not related to an increased risk of emotional distress for patients.
In an interview with HCPLive®, Kanika Sehgal, MBBS, Research Fellow at Mayo Clinic Rochester, explained the current state of C difficile care.
Sehgal recently presented data at 2022 Digestive Disease Week Annual Meeting in San Diego, on the psychological distress in patients at the time of symptom development for CDI.
In the study, the investigators examined adult patients with an index episode of CDI, no history of irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD).
All 8 patients developed abdominal pain that was present for at least 1 day per week and was related to change in bowel movement consistency and frequency.